Effects of Prostatic Inflammation on Clinical Outcomes in Patients with Benign Prostate Hyperplasia

Main Article Content

Asad Mehmood
Muhammad Mohsin Ayaz
Majid Khan Kakakhel


Background: Benign prostate hyperplasia (BPH), a non-cancerous enlargement of the prostate gland, prevalently impacts the aging male population, often disrupting the quality of life with its accompanying urinary symptoms. The intersection between BPH and prostatic inflammation has emerged as a focal point in urological research, with inflammation speculated to exacerbate BPH progression and symptoms. Understanding this relationship is pivotal in refining therapeutic approaches and improving patient outcomes.

Objective: This study aimed to elucidate the effects of prostatic inflammation on the clinical outcomes of patients with BPH, focusing on symptom progression, treatment efficacy, and long-term complications.

Methods: This Study Conducted at Gajju Khan Medical College Swabi, KPK, Pakistan, in the duration from January, 2023 to June, 2023. This prospective cohort study involved 126 men with BPH, categorized into two groups based on the presence (n=63) or absence (n=63) of prostatic inflammation. Data were collected over three years, with assessments including demographic information, clinical histories, and prostate examinations. Primary outcomes measured were the progression of BPH symptoms, urinary function, and prostate size. Secondary outcomes included quality of life, acute urinary retention, the need for surgical intervention, medication efficacy, and long-term complications. Statistical analyses employed included Chi-square tests, t-tests, and ANOVA, with SPSS software.

Results: The group with prostatic inflammation showed significantly more severe symptom progression (p < 0.01), impaired urinary function (p < 0.01), and increased prostate size (p < 0.01) compared to the non-inflamed group. Secondary outcomes also favored the non-inflamed group with better quality of life scores (75.2 ± 5.2 vs. 78.8 ± 4.8, p < 0.01), lower rates of acute urinary retention (20.3% vs. 15.5%, p < 0.01).

Conclusion: Prostatic inflammation significantly worsens the clinical outcomes of BPH, affecting symptom progression, treatment response, and the likelihood of long-term complications. These findings suggest the need for integrated therapeutic strategies that address both BPH and prostatic inflammation to optimize patient care.

Article Details

How to Cite
Mehmood, A., Ayaz, M. M., & Kakakhel, M. K. (2024). Effects of Prostatic Inflammation on Clinical Outcomes in Patients with Benign Prostate Hyperplasia. Journal of Health and Rehabilitation Research, 4(1), 471–476. https://doi.org/10.61919/jhrr.v4i1.463
Author Biographies

Asad Mehmood, Gajju Khan Medical College Swabi KPK Pakistan

MBBS, FCPS- Urology, Assistant Professor.

Muhammad Mohsin Ayaz, Pakistan Kidney & Liver Institute and Research Centre Lahore Pakistan.

Clinical Fellow Kidney Transplant.

Majid Khan Kakakhel, Muhammad Teaching Hospital Peshawar KPK Pakistan

Senior Registrar, Department of Urology.  


Csikós E, Horváth A, Ács K, Papp N, Balázs VL, Dolenc MS, et al. Treatment of benign prostatic hyperplasia by natural drugs. Molecules. 2021;26(23):7141.

Bhat SA, Rather SA, Islam N. An overview of benign prostatic hyperplasia and its appreciation in Greco-Arab (Unani) system of medicine. Asian Journal of Urology. 2022;9(2):109-18.

Jin B-R, Chung K-S, Kim H-J, An H-J. Chinese Skullcap (Scutellaria baicalensis Georgi) inhibits inflammation and proliferation on benign prostatic hyperplasia in rats. Journal of ethnopharmacology. 2019;235:481-8.

Tyagi P, Wang Z, Yoshimura N. Urinary biomarkers and benign prostatic hyperplasia. Current Bladder Dysfunction Reports. 2019;14:31-40.

Karso L. A Multidisciplinary Management Framework for the Treatment of Benign Prostatic Hyperplasia with Focus on Homoeopathy: A Review. Homoeopathic Links. 2020.

Karimi YW. The Prevalence and Association of Metabolic Syndrome With Benign Prostatic Enlargement Among Men Treated at Kenyatta National Hospital: University of Nairobi; 2021.

Lloyd GL, Marks JM, Ricke WA. Benign prostatic hyperplasia and lower urinary tract symptoms: what is the role and significance of inflammation? Current urology reports. 2019;20:1-8.

Meng Y, Yu W, Liu Z, Zhang M, Chen Y, Li S, et al. The inflammation patterns of different inflammatory cells in histological structures of hyperplasic prostatic tissues. Translational Andrology and Urology. 2020;9(4):1639.

Ahmed R, Hamdy O, Awad RM. Diagnostic efficacy of systemic immune-inflammation biomarkers in benign prostatic hyperplasia using receiver operating characteristic and artificial neural network. Scientific Reports. 2023;13(1):14801.

Tsunemori H, Sugimoto M. Effects of inflammatory prostatitis on the development and progression of benign prostatic hyperplasia: A literature review. International Journal of Urology. 2021;28(11):1086-92.

Raafat M, Kamel AA, Shehata AH, Ahmed A-SF, Bayoumi AM, Moussa RA, et al. Aescin protects against experimental benign prostatic hyperplasia and preserves prostate histomorphology in rats via suppression of inflammatory cytokines and cox-2. Pharmaceuticals. 2022;15(2):130.

De Nunzio C, Salonia A, Gacci M, Ficarra V. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. World journal of urology. 2020;38(11):2771-9.

Harley S. Identifying the predictors of change in severity of untreated lower urinary tract symptoms (LUTS) in men: a systematic review. 2018.

Mallhi TH, Ijaz E, Butt MH, Khan YH, Shah S, Rehman K, et al. Benign prostatic hyperplasia. Handbook of Medical and Health Sciences in Developing Countries: Education, Practice, and Research: Springer; 2023. p. 1-19.

Sakalis V, Gkotsi A, Charpidou D, Tsafrakidis P, Apostolidis A. The effect of pharmacotherapy on prostate volume, prostate perfusion and prostate-specific antigen (prostate morphometric parameters) in patients with lower urinary tract symptoms and benign prostatic obstruction. A systematic review and meta-analysis. Central European Journal of Urology. 2021;74(3):388.

Yu Z-J, Yan H-L, Xu F-H, Chao H-C, Deng L-H, Xu X-D, et al. Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Frontiers in Pharmacology. 2020;11:658.

Sugianto R, Tirtayasa P, Duarsa G. A comprehensive review of medical therapy on benign prostatic hyperplasia. Sexologies. 2022;31(1):52-60.

McNally CJ, Ruddock MW, Moore T, McKenna DJ. Biomarkers that differentiate benign prostatic hyperplasia from prostate cancer: A literature review. Cancer Management and Research. 2020:5225-41.

O'Quin C, White KL, Campbell JR, Myers SH, Patil S, Chandler D, et al. Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review. Cureus. 2023;15(12).

Kaltsas A, Kratiras Z, Zachariou A, Dimitriadis F, Sofikitis N, Chrisofos M. Evaluating the Impact of Benign Prostatic Hyperplasia Surgical Treatments on Sexual Health. Biomedicines. 2024;12(1):110.

Pardo-Rodriguez D, Santamaría-Torres M, Salinas A, Jiménez-Charris E, Mosquera M, Cala MP, et al. Unveiling Disrupted Lipid Metabolism in Benign Prostate Hyperplasia, Prostate Cancer, and Metastatic Patients: Insights from a Colombian Nested Case–Control Study. Cancers. 2023;15(22):5465.

Bajic P, Dornbier RA, Doshi CP, Wolfe AJ, Farooq AV, Bresler L. Implications of the genitourinary microbiota in prostatic disease. Current Urology Reports. 2019;20:1-10.

Zhang J, Zhang M, Tang J, Yin G, Long Z, He L, et al. Animal models of benign prostatic hyperplasia. Prostate cancer and prostatic diseases. 2021;24(1):49-57.

Erkoc M, Otunctemur A, Besiroglu H, Altunrende F. Evaluation of quality of life in patients undergoing surgery for benign prostatic hyperplasia. The Aging Male. 2018;21(4):238-42.

Cakir SS, Polat EC, Ozcan L, Besiroglu H, Ötunctemur A, Ozbek E. The effect of prostatic inflammation on clinical outcomes in patients with benign prostate hyperplasia. Prostate International. 2018;6(2):71-4.

Foo KT. What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)? World journal of urology. 2019;37:1293-6.

Kim JH, Lee KS, Kim TH. Evaluation of clinical outcomes of prostatic urethral lift for benign prostatic hyperplasia: an Asian population study. The world journal of men's health. 2020;38(3):338.

Tong Y, Zhou R-y. Review of the roles and interaction of androgen and inflammation in benign prostatic hyperplasia. Mediators of Inflammation. 2020;2020:1-7.

Oseni SO, Naar C, Pavlović M, Asghar W, Hartmann JX, Fields GB, et al. The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer. Cancers. 2023;15(12):3110.

Takahashi S, Takei M, Asakura H, Gotoh M, Ishizuka O, Kato K, et al. Clinical guidelines for female lower urinary tract symptoms. International Journal of Urology. 2021;28(5):474-92.

Walker KA. Inflammation and neurodegeneration: chronicity matters. Aging (Albany NY). 2019;11(1):3.

Paterniti I, Campolo M, Cordaro M, Siracusa R, Filippone A, Esposito E, et al. Effects of different natural extracts in an experimental model of benign prostatic hyperplasia (BPH). Inflammation Research. 2018;67:617-26.

Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia–what do we know? BJU international. 2021;127(4):389-99.

Most read articles by the same author(s)